The Office of Technology Commercialization (OTC) actively
identifies platform-level technologies suitable for start-up company formation.
These companies help create institutional value for the intellectual property
derived from novel inventions made by MD Anderson researchers and faculty.
Since 1987, OTC has been involved in the creation of 11 affiliated companies
that have raised more than $300 million on the strength of MD Anderson
technologies. Four portfolio companies listed on NASDAQ have raised more than
$230 million and funded $25 million in sponsored research at MD Anderson.
Listed below are companies based on MD Anderson technologies.
OTC welcomes inquiries and is pleased to provide information
regarding start-up opportunities. Please contact us for additional information.
Macrophage (now Antigenics)
Established in 1987
Development and commercialization of pharmaceutical products to treat cancer and infectious diseases.
for treatment of colorectal cancer
BioQuest (now Mast
Developing new technologies for anticancer and antiviral treatments that improve the performance of existing drugs and address significant problems such as drug resistance.
R-Gene (now AmpliPhi
Therapy: E1a against Her2/neu overexpressing breast and cervical tumors.
Biomarker discovery and development company
Located in Friendswood, Texas
Focus on proprietary molecular diagnostic assays that assist oncologists in individual risk-stratification for orphan cancers; Occurrence rate <40,000/year.
Based in Houston, Texas
Developing a new generation of oncolytic technology designed to destroy cancer cells while leaving healthy cells unharmed.
Lead product, delta24RGD, is a next-generation adenovirus.
Fem.CadeT Taxol, L.L.C. (Partnered with Cell Therapeutics, Inc.)
Developing and commercializing water soluble paclitaxel cancer therapeutics
IDev Technologies, Inc. (now part of Abbott Vascular)
Development of minimally invasive/interventional radiology devices.
pharmaceutical company focused on pre-clinical and clinical development of
Delivery solutions for therapeutic compounds including siRNA
Located in Houston, Texas
Specialty pharmaceutical company focused on the dermatologic market.
Nanotechnology for optical therapeutics
Developing novel molecular diagnostics that will significantly improve detection and treatment of cancer
Oridigm Corporation (now MediQuest Therapeutics, Inc.)
Development of novel therapeutic drugs based on chemically modified polyamines, a family of important multifunctional cellular molecules. The lead Oridigm program is targeted at cancer.